Miracle and/or Minefield? GLP-1 RA Drugs and Eating Disorders
Abstract Purpose of Review Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the treatment of obesity and type 2 diabetes (T2D), but their rapid uptake has outpaced understanding of their effects in individuals with eating disorders (EDs). GLP-1 RAs produce sustained effects on appetite, satiety, food reward, and energy intake, raising the possibility of markedly different consequences across ED presentations. Recent Findings Preliminary studies suggest potential benefit for binge-eating symptoms, consistent with emerging evidence of overlap between binge eating and reward- and impulse-related pathways. Conversely, appetite suppression and attenuation of compensatory responses to negative energy balance could facilitate or mask restriction in individuals vulnerable to anorexia nervosa (AN) or atypical anorexia nervosa (AAN). Empirical evidence remains sparse. Summary We review neurobiological and genetic evidence relevant to these potentially divergent effects, summarize the clinical literature, and highlight implications for screening and monitoring. Determining who may benefit, who may be harmed, and how to identify risk before treatment should be priorities for future research.
Authors
- Rachel Presskreischer (ORCID: https://orcid.org/0000-0001-5069-1776)
- Cynthia Marie Bulik (ORCID: https://orcid.org/0000-0001-7772-3264)
- Laura Marie Thornton (ORCID: https://orcid.org/0000-0001-9384-7988)
- Amanda Banks
- Anna Meehan
Institutions
- University of North Carolina at Chapel Hill (US)
- Philadelphia VA Medical Center (US)
Publication Details
- Journal
- Current Psychiatry Reports
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1007/s11920-026-01726-9
- Primary Topic
- Eating Disorders and Behaviors
- Type
- article
- Field-Weighted Citation Impact
- 0.00